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ABSTRACT
Several clinical trials evaluating the induction of autoimmune graft-versus-host disease (GVHD) after autol-
ogous bone marrow transplantation (BMT) as antitumor immunotherapy have shown that autologous GVHD
is associated with increased production of interleukin (IL)–10. The induction of autologous GVHD also
segregated with single nucleotide polymorphisms in the IL-10 promoter region (IL-10-592 and IL-10-1082) and
with CA repeats in the first intron of the interferon (IFN)– gene. Polymorphisms within these promoter
regions can significantly modify the cytokine response because of differential transcription factor efficiency.
This study evaluated the relationship between inheritance of polymorphisms within the IL-10 promoter and
in the IFN- gene and the overall survival of patients who received autologous BMT for metastatic breast
cancer. Peripheral mononuclear cells from 87 women enrolled in 3 autologous BMT (plus induction of
autologous GVHD) clinical trials were examined. By using a Cox proportional hazard model, trends in survival
after autologous BMT were analyzed. The model included inheritance polymorphisms of IL-10-592, IL-10-1082,
CA repeats within the first intron of the IFN- gene, estrogen and progesterone receptor status, and stage of
disease. Increased survival was significantly associated with patients having the IL-10-592 promoter allele
associated with high IL-10 production (hazard ratio, 0.23; 95% confidence interval, 0.09-0.55; P  .001). The
effect of the strong IL-10 promoter allele on survival seems to be independent of the development of clinical
autologous GVHD. However, decreased survival was significantly associated with patients having CA repeats
associated with higher IFN- transcription (hazard ratio, 2.34; 95% confidence interval, 1.21-4.54; P  .011).
Inheritance of specific alleles that modify IL-10 and IFN- production may have unexpected effects on the
efficacy of immune-based strategies after autologous BMT. Additional studies are necessary to further define
the influence of IL-10 and IFN- on the immune response after BMT.
© 2005 American Society for Blood and Marrow Transplantation
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rNTRODUCTION
The prognosis of patients with newly diagnosed
reast cancer is largely determined by the size of the
rimary tumor and the presence or absence of nodal
isease. Most of the studies on prognostic factors for
reast cancer recurrence assess markers expressed by the
umor. For example, estrogen receptor (ER) status, pro-
esterone receptor (PR) status, ploidy, proliferative in- p
B&MTex, and cyclin E levels all correlate with survival [1-13].
owever, the role of host factors, ie, genetic differences
mong patients that may help regulate the antitumor
mmune response of the patient, remains unclear. Cyto-
ines seem to play a major role in controlling immune
esponses to tumors [14]. It is interesting to note that
ecent studies suggest that cytokines as well as promoter
olymorphisms that modify cytokine production can
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4lay a signiﬁcant role in autologous bone marrow trans-
lant (BMT) recipients who receive postgrafting im-
une-based therapy [15].
Administration of the immunosuppressive drug
yclosporin A (CsA) after autologous BMT paradoxi-
ally elicits a systemic autoimmune syndrome that
esembles graft-versus-host disease (GVHD). This
yndrome, termed autologous GVHD, is associated with
utoreactive CD8 T cells that recognize major his-
ocompatibility complex (MHC) class II determinants
n association with a peptide from the invariant chain
16]. Miura et al [15]. recently reported that several
ytokines (interleukin [IL]–2, IL-4, IL-10, and inter-
eron [IFN]–) and chemokines (macrophage inﬂam-
atory protein 1) are essential elements involved in
utologous GVHD. Surprisingly, gene expression of
he regulatory cytokine IL-10 as assessed by real-time
olymerase chain reaction (PCR) was greatly in-
reased in patients who developed autologous GVHD
ompared with control patients and patients who did
ot develop this syndrome, whereas the expression of
ther cytokine genes (ie, IL-2 and IL-4) was only
odestly increased. Moreover, the development of
utoreactive killer T cells exhibited a temporal rela-
ionship identical to the increased expression of IL-10
nd IFN- during the development of autologous
VHD. It is interesting to note that susceptibility to
he induction of autologous GVHD was also signiﬁ-
antly associated with single nucleotide polymorphic
ariants in the IL-10 promoter region that control
roduction of this cytokine [15].
IL-10 is a pleiotropic cytokine that, in addition to
locking the production of inﬂammatory cytokines,
an also downregulate the expression of MHC and
ostimulatory molecules [17]. Recent studies suggest
hat IL-10 can suppress the development of GVHD
fter allogeneic BMT [18]. Because of these pleiotro-
ic regulatory effects, IL-10 may alter the graft-ver-
us-tumor effect after BMT [18-21]. Although it is
nclear whether autologous GVHD has a signiﬁcant
ntitumor effect for patients with metastatic breast
ancer, [22] inheritance of single nucleotide polymor-
hisms in the IL-10 promoter region that modify the
roduction of this cytokine may confound any immu-
otherapeutic effects of autologous GVHD or any
ther immune-based therapies. Moreover, dysregula-
ion of IL-10 production may directly suppress anti-
umor immune responses that could inﬂuence the
verall survival of patients after autologous BMT.
To explore this possibility, single nucleotide poly-
orphisms in the IL-10 promoter regions (IL-10-592
nd IL-10-1082) were evaluated in patients undergoing
utologous BMT with the induction of autologous
VHD. Additionally, CA repeats within the ﬁrst in-
ron of the IFN- gene that inﬂuence transcription
ere also assessed in these patients. These studies
eveal that inheritance of polymorphic alleles control- p
56ing cytokine gene transcription signiﬁcantly corre-
ates with overall survival after autologous BMT and
ay signiﬁcantly inﬂuence the efﬁcacy of immune-
ased therapies.
ATERIALS AND METHODS
atients
Women between 24 and 60 years of age with
ither metastatic or locally advanced (inﬂammatory)
reast cancer in complete or partial response to che-
otherapy or with 4 axillary lymph nodes after
tandard adjuvant chemotherapy were included in this
tudy, as previously described [22,23]. All patients
ith informed consent were enrolled in 1 of 3 insti-
utional review board–approved autologous GVHD
rials at the Johns Hopkins Hospital. The studies
ncluded a phase I trial and 2 phase II trials in patients
ith metastatic, locally advanced, or high-risk multi–
ode-positive breast cancer.
reparative Regimens and Induction of
utologous GVHD
The patients were prepared for autologous BMT
y treatment with cyclophosphamide and thiotepa be-
ore autologous bone marrow rescue, as previously
escribed [23]. Autologous GVHD was induced by
he intravenous administration of CsA (2.5 mg/kg/d
or 28 days) beginning on the day of transplantation.
ecombinant IFN- (0.025 mg/m2; National Cancer
nstitute, Bethesda, MD) was administered subcutane-
usly every other day from days 7 through 28 after
ransplantation to induce the upregulation of MHC
lass II determinants (target antigen of autologous
VHD) and to enhance tumor cell recognition. One
roup of control patients (n  6) included in this
nalysis underwent autologous BMT by using the
ame preparative regimens but without the adminis-
ration of CsA and IFN-. Previous analyses revealed
hat the induction of clinical autologous GVHD did
ot have a signiﬁcant effect on survival in patients with
igniﬁcant metastatic disease [22].
enomic DNA Extraction
Heparinized peripheral blood was collected from
he patients after informed consent was obtained. Pe-
ipheral blood mononuclear cells were separated by
sing density-gradient centrifugation, and genomic
NA was prepared from peripheral blood mononu-
lear cells with DNAzol reagent (Life Technologies,
aithersburg, MD) as previously described [15]. Total
NA was puriﬁed with TRIzol reagent (Life Tech-
ologies). The puriﬁed RNA was dissolved in diethyl-
yrocarbonate–treated distilled water [15].
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IL-10 Promoter Polymorphisms and Survival after Autologous BMT
Bromoter Polymorphisms by Allele-Specific PCR
An allele-speciﬁc PCR (ASPCR) was used to de-
ect the G¡A transition polymorphism at position
1082 of the IL-10 gene [15]. Three primers were used
or ASPCR: the 3= primer (5=-GCAACACTCCTC-
TCGCAAC-3=) was combined with either the 5=
rimer (1082G: 5=-CTATCCCTACTTCCCCC-3=)
omplementary to the IL-10-1082 G allele or the 5=
rimer (1082A: 5=-CCTATCCCTACTTCCCCT-3=)
omplementary to the IL-10-1082 A allele. Primers
082G and 1082A differ only in their 3= terminal nucle-
tide. ASPCR was used to detect the C¡A transition
olymorphism at position -592 of the IL-10 gene. The
= primer (5=-TGAGAAATAATTGGGTCCCC-3=)
as combined with either the 5= primer (592C: 5=-ATC-
TGTGACCCCGCCTGTC-3=) complementary to
he IL-10-592 C allele or the 5= primer (592A: 5=-ATC-
TGTGACCCCGCCTGTA-3=) complementary to
he IL-10-592 A allele. DNA (1 g) was PCR-ampliﬁed
hrough 30 cycles (95°C for 30 seconds, 60°C for 1
inute, and 72°C for 1 minute) with sense primers and
ntisense primers. PCR products (1 L) plus modiﬁed
enescan molecular weight markers (Applied Biosys-
ems-Perkin Elmer, Foster City, CA) were sized by
sing an ABI 377 automatic sequencer equipped with
he computer program Genotyper 2.0 (Applied Bio-
ystems-Perkin Elmer). Previous studies revealed that
hese were optimal conditions for detecting polymor-
hisms within the IL-10 promoter. In addition, inher-
tance of speciﬁc alleles was conﬁrmed by repeat assays.
ingle nucleotide polymorphisms in the promoters for
L-6, tumor necrosis factor , macrophage inﬂammatory
rotein 1, and CCR5 were also assessed by ASPCR as
reviously reported [15].
ntron Polymorphisms by PCR and
el Electrophoresis
The CA repeat region of the ﬁrst intron was
mpliﬁed by using the IFN- sense and antisense
rimers, respectively: GCTGTCATAATAATA-
TCAGAC and CGAGCTTTAAAAGATAGT-
CC [24]. Products were separated on a polyacryl-
mide gel containing 12% acrylamide/bis acrylamide
19:1) at 35 mA for 4 hours. After electrophoresis, gels
ere stained with ethidium bromide and visualized
ith UV light for allelic determination.
uantification of IL-10 and IFN- Expression
IL-10 and IFN- gene expression in peripheral
lood mononuclear cells was quantiﬁed by real-time
CR by using the TaqMan assay (Applied Biosystems-
erkin Elmer) in the ABI-PE Prism 7700 detection
ystem, as previously described [15]. The primers and
uorogenic probes were purchased from Applied Bio-
ystems-Perkin Elmer. IL-10 and IFN- messenger
NA (mRNA) levels were expressed as the absolute o
B&MTumber of copies normalized against mRNA levels of
he housekeeping gene glyceraldehyde phosphate de-
ydrogenase (GAPDH). The difference in ampliﬁca-
ion was determined as follows: 1/(cycle threshold
ytokine  cycle threshold GAPDH).
tatistical Analysis
Overall survival was calculated from the ﬁrst day
f transplantation to the date of death or last follow-
p. Survival curves were computed by using the
aplan-Meier method for each factor: IL-10-592 and
L-10-1082 promoter genotypes, IFN-, stage of dis-
ase, and ER/PR status. Data stratiﬁed by the pres-
nce or absence of clinical autologous GVHD were
valuated by Gehan-Breslow survival analysis (Sig-
aStat 3.0; Systat Software, Point Richmond, CA). A
ultivariate analysis of overall survival was performed
y using the Cox proportional hazard model, which
ncluded IL-10-592 and IL-10-1082 promoter geno-
ypes, CA repeats within the ﬁrst intron of the IFN-
ene, stage of disease, and ER/PR status. Stage and
R/PR status were forced into the model because of
heir known prognostic implications on survival [24].
actors such as age and race and the presence or
bsence of clinical autologous GVHD did not con-
ribute signiﬁcantly and were not included in the ﬁnal
odel presented, whereas the promoter polymor-
hisms for IL-10 and IFN- had a signiﬁcant effect on
urvival [22]. The individual promoter polymorphisms
IL-10-592, IL-10-1082, and IFN-) and stage of disease
ere categorized in groups of 3 as ordered variables:
L-10-592—AA-weak, AC-intermediate, and CC-
trong; IL-10-1082 haplotypes—AA-weak, AG-inter-
ediate, and GG-strong; IFN- CA repeat polymor-
hisms—X/X, weak, 2/X, intermediate, and 2/2,
trong; and stage of disease—I/II, III, and IV, respec-
ively.
ESULTS
tudy Population
As summarized in Table 1, patient ages ranged
rom 24 to 60 years (mean, 42.7 years; SD, 7.9 years).
he race distribution was 78% Caucasian, 17% African
merican, and 4.6% other. Upon diagnosis of breast
ancer, 46% of patients had stage I or II disease, 17%
ad stage III disease, and 36% had stage IV disease.
ost patients (54%) tested positive for ER, PR, or
oth; 33% tested negative for both ER and PR, and
he status of the remaining 13% of the patients was
nknown. Eighty-one patients underwent autologous
VHD induction by the administration of CsA and
FN-, and 6 control autologous BMT patients did
ot receive this experimental therapy (and were in-
luded in the autologous GVHD–negative population
f patients). Of the 81 patients entered onto the ex-
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4erimental autologous GVHD induction protocols,
9 patients developed clinical and histologic evidence
f autologous GVHD, as previously described [21].
here was no correlation between autologous GVHD
tatus (positive or negative), age, race, and stage of
isease or ER/PR status. The allelic frequencies of the
L-10-592 and IL-10-1082 promoters and the IFN-
A intron repeats are also summarized in Table 1.
he relative frequencies are comparable to the fre-
uencies previously reported for the general popula-
ion in the United States [25-27].
urvival by Stage
Univariate analysis by stage of disease for the 87
atients was performed by Kaplan-Meier and log-rank
esting. Figure 1 presents the Kaplan-Meier estimates
y stage of disease, grouped into stages I/II, III, and
V. The results, as expected, suggest that stage of
isease at presentation or treatment is a likely factor in
redicting survival. The poorest survival was observed
n patients with stage IV disease (P  .001), whereas
atients with stage I or II disease had the best survival. In
hemultivariate analysis using a Cox proportional hazard
odel that included the IL-10-592 and IL-10-1082 alleles,
FN- CA repeats, ER/PR status, and stage as variables,
tage IV disease had a statistically signiﬁcant negative
ffect on survival compared with stages I and II com-
ined (hazard ratio, 8.3; 95% conﬁdence interval [CI],
able 1. Patient Characteristics (N  87)
Variable Data
ge (y)
Mean 42.7
Range 24-60
SD 7.9
ace
Caucasian 68 (78%)
African American 15 (17%)
Other/unknown 4 (4.6%)
tage
I/II 40 (46%)
Any III 15 (17%)
IV 31 (36%)
R/PR
Negative 29 (33%)
Positive 47 (54%)
Unknown 11 (13%)
llelic frequencies
IL-10-592
AA 7 (8.0%)
AC 38 (43.7%)
CC 42 (48.3%)
IL-10-1082
AA 28 (32.1%)
AG 35 (40.2%)
GG 24 (27.6%)
FN- CA repeats
2/2 17 (19.5%)
2/X 45 (51.7%)
X/X 25 (28.8%).4-28.1). There was no statistically signiﬁcant differ- a
58nce, however, between stage III patients and those
ith stage I or II disease (hazard ratio, 0.66; 95% CI,
.11-4.0). The overall survival of all patients on the
utologous GVHD induction protocol was mod-
stly improved compared with that of recent histor-
cal controls by using conventional autologous
MT. However, there was no signiﬁcant difference
n the overall survival of patients who developed
linical evidence of autologous GVHD (erythematous
ash or grade 2 biopsy-conﬁrmed skin GVHD) com-
ared with the patients who did not develop this
utoaggression syndrome [22] (Figure 2).
igure 1. Overall survival of patients with metastatic breast cancer
reated with autologous BMT and autologous GVHD induction.
f the 86 patients evaluated, 40 (46%) had stage I or II disease, 15
17%) had stage III disease, and 31 (36%) had stage IV disease.
UTO indicates autologous.
igure 2. Overall survival in patients with clinical autologous
VHD and in patients who did not develop any clinical evidence of
utoaggression. Of the 87 patients evaluated, 29 developed clinical
utologous GVHD, and 58 did not develop any evidence of clinical
utoaggression. AUTO indicates autologous.
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IL-10 Promoter Polymorphisms and Survival after Autologous BMT
BL-10 Promoter Polymorphisms
Previous studies revealed that allelic variants in
he promoter region for IL-10 regulate production
f this cytokine [25-27]. The IL-10-592 promoter
lleles AA, AC, and CC are associated with low,
edium, and high IL-10 cytokine production, re-
pectively [25]. The Kaplan-Meier estimates using
L-10-592 alleles in a univariate analysis are shown
n Figure 3A. The IL-10-592 and IL-10-1082 single
ucleotide polymorphisms in the promoter region
orm stable haplotypes that correlate with low, in-
ermediate, and high IL-10 production [25-27]. Ad-
itional univariate analysis of survival by inherited
L-10-592 and IL-10-1082 paralleled the IL-10-592
urvival curves. Improved survival was associated
ith inheritance of the haplotype associated with
igh IL-10 production, and poor survival correlated
ith inheritance of the low IL-10 production hap-
otype.
Because it was expected that the induction of clinical
utologous GVHD would correlate with overall survival
nd because this autoaggression syndrome is associated
ith high IL-10 production, the data were stratiﬁed into
atients with and without clinical autologous GVHD.
nexpectedly, the effects of the IL-10-592 promoter ge-
otypes on survival were similar in the patients who did
nd did not develop clinical autologous GVHD (Figure
B and C). The overall survival of patients inheriting the
L-10-592 CC genotype is superior (P .001) to that of
atients inheriting either the AC or the AA genotype.
urvival in patients with the AC genotype was signif-
cantly (P  .007) better than the survival of patients
ith the AA genotype. The beneﬁt of genotype inher-
tance does not seem to be dependent on clinical
utologous GVHD but acts independently.
Analysis of the patient population in these studies
evealed that overall survival was correlated with the
nheritance of the IL-10 promoter allelic variants.
ith use of the Cox proportional hazards model de-
cribed previously, improved survival after BMT was
igure 3. Overall survival and inheritance of the IL-10-592 pro
nheritance of the IL-10-592 promoter alleles. A, All patients. B, Pa
vidence of clinical autoaggression. AUTO indicates autologous.igniﬁcantly associated with the CC allele of IL-10-592 h
B&MThat is associated with strong IL-10 promoter activity
hazard ratio, 0.23; 95% CI, 0.09-0.55; P  .001).
omparatively, the poorest survival was observed in
atients who had the weak AA IL-10-592 promoter
llele, and intermediate survival was observed in pa-
ients with the IL-10-592 AC promoter allele.
FN- Intron Polymorphism: CA Microsatellites
Previous studies have indicated that the CA repeat
lleles within the ﬁrst intron of the IFN- gene cor-
elate with in vitro production of IFN- [27]. Patient
urvival was assessed with stratiﬁcation of the inheri-
ance of the CA repeat alleles into low (X/X), medium
X/2), and high (2/2) producers. The Kaplan-Meier
stimates for the IFN- CA repeat alleles in this pa-
ient population are shown in Figure 4A and suggest
hat they may also play a role in survival. Surprisingly,
hen stratifying for autologous GVHD, this effect of
he IFN- CA repeat alleles could be seen and was
ost pronounced only in the patients who developed
linical autologous GVHD (Figure 4B). Overall sur-
ival was signiﬁcantly (P .001) improved for patients
nheriting the X/X allele compared with the survival
f patients inheriting the 2/X and 2/2 alleles. In con-
rast, inheritance of the IFN- CA repeat alleles did
ot seem to inﬂuence the overall survival of patients
ho did not develop clinical evidence of autologous
VHD (Figure 4C). In the multivariate analysis using
he Cox proportional hazards model described previ-
usly, inheritance of CA repeat alleles within the ﬁrst
ntron of the IFN- gene also seemed to indepen-
ently affect survival in this patient population. De-
reased survival was signiﬁcantly associated with pa-
ients who had the 2/2 CA repeat allele (hazard ratio,
.34; 95% CI, 1.21-4.54; P  .011). Comparatively,
atients with the introns correlating with low or mod-
rate IFN- transcription had better overall survival.
ytokine mRNA Transcription
Studies were undertaken to evaluate whether in-
alleles. Kaplan-Meier survival estimates demonstrate survival by
with clinical autologous GVHD. C, Patients who did not developmoter
tientseritance of the different IL-10 promoter alleles cor-
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4elates with active gene transcription in the autolo-
ous BMT patient population in this study. Peripheral
lood mononuclear cells harvested between days 19
nd 26 after BMT were assessed for IL-10 gene ex-
ression by quantitative PCR. The results from pa-
ients who developed clinical autologous GVHD and
rom patients who did not develop this autoaggression
yndrome were compared separately because the de-
elopment of autologous GVHD is associated with
igh levels of IL-10 mRNA transcripts [15]. As illus-
rated in Figure 5, IL-10 expression in peripheral
lood mononuclear cells from both groups of patients
ho inherited the high promoter genotype (-592; CC)
ad signiﬁcantly higher levels (P  .01) of IL-10
RNA compared with patients who had the moderate
AC) promoter allele. In comparison, patients with the
A genotype had the lowest levels of IL-10 mRNA.
he number of patients with this genotype, however,
as too low to allow for an adequate statistical com-
arison. Analyses of peripheral blood mononuclear
ells from control autologous BMT patients were sim-
lar, with levels of IL-10 mRNA transcripts approxi-
ately 2-fold greater in individuals who had the high
romoter genotype compared with the low or mod-
rate promoter genotypes (2.1 versus 1.1 and 0.9 rel-
tive transcript levels; data not shown). Although
hese studies correlate the inheritance of the IL-10
romoter alleles with active gene transcription, they
o not quantify the production of IL-10. The results,
owever, provide evidence that the cells circulating in
he peripheral blood are actively producing IL-10
RNA and that the levels of message for this cytokine
ssessed directly ex vivo correlate with the inheritance
f the IL-10 promoters.
IFN-mRNA transcript levels in peripheral blood
ononuclear cells were also assessed directly ex vivo
y quantitative PCR. Data were stratiﬁed on the basis
f the presence or absence of clinical autologous
VHD. Although the levels of mRNA transcripts
igure 4. Overall survival and inheritance of the CA intron repea
urvival by inheritance of the CA intron repeats within the IFN- ge
ho did not develop evidence of clinical autoaggression. AUTO inere low, there was a general correlation with tran-
h
A
60cript levels and inheritance of the CA intron repeats
ithin the IFN- gene (Table 2). The highest levels of
ranscripts were observed in both patient groups with
he 2/2 genotype, and the lowest levels were detected
n patients who inherited the X/X genotype.
ISCUSSION
Cytokines play an important role in both immune
econstitution and GVHD after bone marrow or he-
atopoietic stem cell transplantation [15]. Recent
tudies in patients undergoing autologous BMT with
he experimental induction of autologous GVHD as
mmunotherapy suggest that cytokines may also mod-
fy immune responsiveness. For example, the induc-
igure 5. IL-10 production and inheritance of IL-10-592. Periph-
ral blood mononuclear cells were harvested from autologous BMT
ecipients and assessed ex vivo (between days 19 and 25 after BMT)
or IL-10 mRNA expression by quantitative PCR. Patients were
tratiﬁed according to whether they developed clinical autologous
VHD. Data expressed as relative transcripts  104 standardized
gainst the glyceraldehyde phosphate dehydrogenase (GAPDH)
in the IFN- gene. Kaplan-Meier survival estimates demonstrate
ll patients. B, Patients with clinical autologous GVHD. C, Patients
autologous.ousekeeping gene. The median is indicated for each group (——).ts with
ne. A, AUTO indicates autologous.
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IL-10 Promoter Polymorphisms and Survival after Autologous BMT
Bion of active autoaggression after autologous BMT
orrelates with high levels of IL-10 production—a
ytokine that can provide an important signal for
he proliferation and survival of autoreactive T cells
15,28]. Moreover, the induction of autologous
VHD strongly correlates with the inheritance of a
ingle nucleotide polymorphic determinant within the
L-10 promoter region that has strong promoter ac-
ivity associated with high IL-10 production [15]. In
his regard, recent studies by Westendorp et al [29].
ndicate that genetic factors account for substantial
ifferences in the ability to produce IL-10. Differ-
nces in IL-10 production may be an important risk
actor for disease susceptibility and disease prognosis.
L-10, with its immunomodulating activities, may also
ave confounding effects in the setting of immuno-
herapy.
In this study, survival after autologous BMT
ith immune modulation (induction of autologous
VHD) for breast cancer was differentially associ-
ted with inheritance of IL-10 promoter allelic vari-
nts. The most pronounced effect on overall sur-
ival was the inheritance of allelic variants within
he IL-10 promoter at position 592. Patients inher-
ting the IL-10-592 promoter allele (CC) associated
ith high IL-10 production had signiﬁcantly im-
roved overall survival compared with patients in-
eriting the allelic variants at this site associated
ith weak (AA) or modest (AC) IL-10 promoter
ctivity. On the basis of the ﬁndings that high IL-10
roduction and inheritance of the high promoter
enotype correlated with the induction of clinical
utologous GVHD, it was expected that overall
urvival would be demonstrable only in patients
eveloping this autoaggression syndrome [15]. The
ffects of the IL-10-592 promoter genotypes, how-
ver, were also quite evident in the patients who did
ot develop autologous GVHD. The beneﬁt of ge-
otype inheritance does not seem to be dependent
n the development of clinical autologous GVHD,
ut rather acts independently. Similarly, improved
able 2. Levels of IFN- mRNA Transcripts and IFN- CA Intron
enotype Inheritance
Genotype
Relative Transcripts (IFN--GAPDH)
AutoGVHD positive AutoGVHD negative
2/2 6.7  1.2 1.6  0.8
2/X 4.5  0.4 0.5  1.1
X/X 1.1  0.2 0.9  0.7
evels of IFN- were assessed in peripheral blood mononuclear
cells harvested from patients 19 to 26 days after autoBMT by
quantitative PCR. Values were standardized against the glycer-
aldehyde phosphate dehydrogenase (GAPDH) housekeeping
gene.
uto indicates autologous.urvival in patients inheriting the 592/1082 haplo- t
B&MType associated with high IL-10 production in both
atient groups paralleled the results with the IL-10-592
trong promoter allele [15]. These results are not
urprising, because the combination of single nucleo-
ide polymorphisms within this stable haplotype are,
n fact, strongly linked. Previous studies suggest that
usceptibility to the induction of autologous GVHD is
referentially associated with inheritance of IL-10-1082
romoter genotypes, whereas correlation with the IL-
0-592 allelic variants is much less pronounced. Inad-
quate sample size may account for the inability to
emonstrate linkage between the IL-10-592 and IL-10-
082 allelic variants evaluating susceptibility to the in-
uction of autologous GVHD. However, the poly-
orphic sites at positions 592 and 1082 within the
L-10 promoter region may be linked to different
ranscription factors [30,31]. Differential activation
nd transcription of the IL-10 gene may contribute
igniﬁcantly to the susceptibility to induce autologous
VHD.
The results from these studies indicate that inher-
tance of the strong promoter alleles is also associated
ith higher IL-10 gene expression after autologous
MT. Ex vivo analysis reveals that peripheral blood
ononuclear cells actively produce IL-10 mRNA and
hat the levels of IL-10 mRNA correlate with inheri-
ance of promoter alleles associated with differential
roduction of IL-10. Because many factors can inﬂu-
nce cytokine gene transcription and translation (cell
ctivation and costimulation), the levels of IL-10 pro-
uced may not correlate with the inheritance of the
llelic variants of the IL-10 promoter. Although levels
f IL-10 mRNA generally correlate with production
f the cytokine, it remains uncertain whether sufﬁ-
ient IL-10 is produced to have a systemic effect on
mmune reconstitution after autologous BMT [15].
owever, production of IL-10 at the local level (ie,
ymph node or at the tumor site) may have a greater
ffect on the immune response. Nevertheless, the re-
ults from these studies raise the possibility that the
egulatory cytokine IL-10 may have a paradoxical role
n promoting antitumor responses during reconstitu-
ion of the immune system after autologous BMT.
The apparent paradoxical association of the IL-10-592
romoter genotypes with overall survival (primarily the
ssociation of the high IL-10 producer genotype with
mproved survival) in these studies is unclear. The pro-
oter genotypes lead to the differential production of
L-10, mostly by limiting the efﬁciency of transcrip-
ion [30-32]. IL-10, primarily a type 2 cytokine, has
oth positive and negative regulatory effects on the
mmune system [17,28,33-36]. In addition to inhibit-
ng MHC class II antigen expression, IL-10 can also
uppress the expression of the costimulatory cell-sur-
ace accessory molecule B-7 [37]. Downregulation of
-7 and MHC class II antigen expression can result in
he failure to activate antigen-speciﬁc T cells. Fur-
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4hermore, failure to provide the necessary costimula-
ory signal (mediated through B-7) may lead to T-cell
nergy [38,39]. Recent studies suggest that IL-10 also
imits or suppresses GVHD after allogeneic BMT by
nhibiting inﬂammatory cytokine production. These
ytokines contribute signiﬁcantly to early transplant-
elated mortality [40,41]. High IL-10 levels after au-
ologous BMT may be protective by inhibiting the
roduction of the inﬂammatory cytokines often exac-
rbated by bacterial infections. In these studies, how-
ver, early transplant-related mortality occurred in
nly 4 patients, and each inherited different promoter
lleles (data not shown). The remainder of the deaths
ere due to tumor progression. In contrast to the
egative effects of IL-10 on the immune response,
L-10 can augment the proliferative response of IL-2–
nd IL-4–activated T cells stimulating both cytotoxic
-cell activity and B cell–dependent antibody [42].
dditional studies also reveal that this cytokine can
romote survival and proliferation of immature thy-
ocytes and promote the proliferation of autoreactive
cells [43]. The conditioning regimen used for au-
ologous BMT may damage the thymus and lead to
he release of autoreactive T cells. In this setting,
L-10 may support the growth of autoreactive T cells
hat are capable of recognizing tumor-associated an-
igens derived from self-proteins.
The results from these studies also indicate that
rst intron CA repeat variants in the IFN- gene may
lso have a signiﬁcant effect on survival. These intron
ariants inﬂuence the rate of IFN- gene transcription
24]. Decreased survival was signiﬁcantly associated
ith patients who had CA intron repeats associated
ith high IFN- transcription. Unexpectedly, in the
nivariate analysis, the effect of the intron CA repeat
ariants on overall survival was demonstrable only in
atients who developed clinical evidence of autolo-
ous GVHD; the IFN- intron alleles had no effect
n overall survival for patients who did not develop
linical autologous GVHD. The apparent inverse re-
ationship between decreased survival and inheritance
f the CA intron repeat for high IFN- transcription
s surprising, because this cytokine plays a crucial role
n the antitumor immune response. The complexity of
he effects of IFN- in vivo may outweigh the in vitro
bservations that autoreactive T-cell responses can be
otentiated by upregulation of MHC antigens. At
resent, it is also unclear whether the increased risk
ssociated with high inheritance of the intron associ-
ted with high IFN- production is due to other
ontributing factors, including polymorphisms in
ther cytokine promoters. Any conclusion, however,
ust be guarded, because the patient population is
elatively small and because effects due to patient
eterogeneity cannot be totally excluded.
In conclusion, these studies reveal that overall
urvival after autologous BMT in patients with breast
62ancer correlates with polymorphic genetic factors
hat control cytokine (IL-10 and IFN-) production.
he paradoxical ﬁnding that factors governing high
L-10 production correlate with improved survival
ertainly raises some interesting questions. IL-10 may
otentiate antitumor immune mechanisms by promot-
ng proliferation of autoreactive T cells, including the
ffector cells that mediate autologous GVHD. The ef-
ects of IFN-, particularly in autologous GVHD, seem
o be complex and need to be further deﬁned. Control
f IL-10 and IFN- production seems to play a critical
ole in the reconstitution of the immune system and
ay inﬂuence the overall survival and outcome of
ndividual patients with otherwise similar prognostic
actors. It is interesting to note that ongoing studies
valuating variants within other cytokine promoters
ave not revealed any signiﬁcant effect on survival,
hus suggesting that that correlation with survival is
imited to speciﬁc cytokines rather than being a broad
eneralized effect. At present, it is also unclear
hether the effects of these polymorphisms are lim-
ted to patients receiving autologous BMT. Neverthe-
ess, these polymorphisms may identify patients who
ould beneﬁt from high-dose chemotherapy and au-
ologous stem cell rescue. Although the present stud-
es are correlative, they provide new insights into the
omplexity of the reconstitution of the immune sys-
em after autologous BMT and identify potential fac-
ors that may contribute to the induction of an anti-
umor response. Certainly, additional in vitro and ex
ivo studies of patients with breast cancer and with
ther malignancies after autologous BMT are neces-
ary to further understand the inﬂuence of IL-10,
FN-, and other cytokine transcription control
echanisms on immune response and survival.
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